These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...

Bayer said its Elinzanetant drug, which targets some symptoms produced by endocrine therapy in women with breast cancer, met all primary and secondary endpoints in a study. The German pharmaceutical ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...